Shasun Pharma Solutions, a UK-based, wholly-owned subsidiary of Shasun Chemicals & Drugs, has signed a non-exclusive licensing agreement with H Lundbeck A/S, a research-based Danish company engaged in finding new drugs for the treatment of central nervous system (CNS) disorders. According to a release issued today, Shasun Pharma has granted H Lundbeck A/S the use of its proprietary cross-coupling technology (also known as Buchwald technology) to manufacture and commercialise new active pharmaceutical ingredients (APIs).
